View Older Stories
-
Edwards Lifesciences (EW) PT Raised at Bernstein SocGen After 'Another strong, clean quarter'
-
Edwards Lifesciences (EW) Reiterated at Buy by Stifel After 'Encouraging' Q1 Earnings
-
Edwards Lifesciences (EW) PT Raised to $90 at Truist Securities
-
Edwards Lifesciences (EW) PT Raised to $110 at Barclays
-
Edwards Lifesciences (EW) PT Lowered to $85 at Canaccord
-
Edwards Lifesciences (EW) PT Raised to $100 at BTIG
-
After-hours movers: INTC, AMD, ARM, MXL, NEM, APPF, FIX, EW
-
Edwards Lifesciences (EW) Tops Q1 EPS by 5c; offers guidance
-
Q1 MedTech quarterly preview: BTIG
-
TD Cowen: 'Edwards Lifesciences (EW) Share Gain Story Includes TAVR and TMTT Chapters'
-
Wolfe Research Upgrades Edwards Lifesciences (EW) to Outperform
-
Edwards reports sustained benefits from EVOQUE heart valve system
-
Piper Sandler's Key Takeaways From CRT 2026
-
Edwards Lifesciences sets goal to help 2 million more patients by 2030
-
Stifel Reiterates Buy Rating on Edwards Lifesciences (EW)
-
Edwards Lifesciences (EW) Misses Q4 EPS by 4c, Beats on Revenue; Offers Q1 Guidance
-
Edwards Lifesciences (EW) PT Raised to $110 at Stifel
-
Edwards Lifesciences (EW) call put ratio 1 call to 2.7 puts into updated guidance
-
Court blocks Edwards Lifesciences' JenaValve acquisition
-
Bernstein Highlights Top U.S. Medtech 2026 Picks: 'Sector Poised For a Rebound'
-
TD Cowen Upgrades Edwards Lifesciences (EW) to Buy
-
Edwards Lifesciences (EW) PT Raised to $105 at Stifel: Well-Positioned for 2026
-
BofA’s six MedTech picks for 2026 on strong earnings growth
-
Citi Adjusts Large Cap Recommended List, Micron (MU) Removed
-
JPMorgan Upgrades Edwards Lifesciences (EW) to Overweight
-
Edwards Lifesciences (EW) PT Raised to $89 at Canaccord Genuity
-
BTIG on Edwards Lifesciences (EW): 'Right on Time: TAVR National Coverage Analysis Opened for Review'
-
Edwards Lifesciences (EW) PT Raised at Bernstein on Growth Upside
-
Edwards Lifesciences (EW) PT Raised to $92 at UBS
-
Edwards Lifesciences (EW) PT Raised at RBC Capital; 'A Catalyst Rich Year in 2026 and Beyond'
-
Edwards Lifesciences (EW) PT Raised to $100 at Stifel
-
Edwards Lifesciences (EW) PT Raised to $92 at Truist Securities
-
Edwards Lifesciences (EW) PT Raised to $89 at Canaccord Genuity
-
Edwards Lifesciences (EW) PT Raised to $103 at BTIG
-
Edwards Lifesciences provides 2026 financial guidance at investor conference
-
UBS Reiterates Neutral Rating on Edwards Lifesciences (EW) Ahead of Investor Day
-
Piper Sandler Highlights 'Lots Of Focus On New Catalysts' at Edwards Lifesciences (EW)
-
Edwards Lifesciences (EW) PT Raised to $90 at Bernstein After a 'Strong Beat'
-
Edwards Lifesciences (EW) PT Raised to $84 at Canaccord Genuity
-
Raymond James Upgrades Edwards Lifesciences (EW) to Outperform
-
Edwards Lifesciences (EW) Tops Q3 EPS by 8c; raises guidance
-
Wolfe Research Upgrades Edwards Lifesciences (EW) to Peerperform
-
Jefferies Upgrades Edwards Lifesciences (EW) to Buy
-
Edwards Lifesciences (EW) PT Raised to $87 at Truist Securities
-
Edwards presents positive trial data for heart valve systems at TCT
-
Edwards SAPIEN 3 valve shows comparable seven-year outcomes to surgery
-
Oppenheimer Downgrades Edwards Lifesciences (EW) to Perform, 'Realizing LRP Challenging'
-
Piper Sandler Reiterates Overweight Rating on Edwards Lifesciences (EW)
-
Evercore ISI Upgrades Edwards Lifesciences (EW) to Outperform
-
Needham: 'we believe that the Section 232 investigation creates a new overhang for the already beleaguered medical device sector'

